The OpenAI Trade Isn't Microsoft Anymore. Here's Where Smart Money May Be Looking.

The article argues Nvidia is the preferred way to gain exposure to OpenAI ahead of a potential IPO, citing OpenAI’s expected $115 billion spend through 2029 and its dependence on AI chips. Nvidia is highlighted as the dominant GPU supplier, with fiscal Q1 2027 revenue up 85% year over year and net income more than tripling. The piece is bullish on Nvidia’s pricing power and demand outlook, while suggesting Microsoft is no longer the best direct OpenAI proxy.

Analysis

The market is likely underestimating how much OpenAI’s scaling path monetizes Nvidia indirectly rather than directly. The key second-order effect is that OpenAI’s spend is not a one-off capex burst; it is a recurring compute-intensity loop where each product milestone drives more inference demand, which then forces higher GPU procurement and keeps pricing power with the chip supplier rather than the model developer. That makes NVDA the cleaner way to express the AI demand curve over the next 6-18 months, while MSFT faces a more ambiguous payoff from funding a competitor that is increasingly building its own distribution and product stack.

MSFT’s problem is strategic, not just financial: the more it ships competing AI products, the less “embedded exposure” it has to OpenAI economics, and the higher the odds OpenAI diversifies away from its infrastructure and cloud dependencies over time. That creates a subtle headwind for Microsoft’s AI narrative even if Azure remains strong, because investors may need to separate cloud growth from OpenAI optionality. In contrast, NVDA benefits from a broad oligopoly of buyers—hyperscalers, model labs, and startups—so any one customer’s bargaining power is diluted; that is the real reason pricing/margin pressure looks manageable despite rising competitive rhetoric.

The contrarian risk on NVDA is that consensus may be too complacent about supply normalization and architectural substitution over a 12-24 month horizon. If inference efficiency improves faster than expected, or if custom silicon from hyperscalers and select partners meaningfully offsets GPU demand, growth can decelerate before revenue rolls over, which is usually when multiples compress hardest. For AVGO and AMD, the setup is more nuanced: they are the natural second-derivative beneficiaries if buyers seek diversification away from Nvidia, but they also need proof that share gains are structural rather than opportunistic.

Key Decisions for Investors

• Long NVDA into OpenAI IPO-related headlines over the next 1-3 months; target is continued multiple support from incremental AI demand visibility, with a stop if hyperscaler spending commentary softens materially.
• Reduce or hedge MSFT AI-exposure narratives versus core cloud fundamentals over the next 1-2 quarters; consider a relative-value short MSFT / long NDAQ? No—prefer short MSFT vs long NVDA if the goal is to isolate AI infra from AI app/platform cannibalization.
• Initiate a basket long AVGO/AMD vs short NVDA on a 6-12 month horizon only if evidence emerges of GPU supply normalization or custom silicon wins accelerating; otherwise this pair has unfavorable timing risk.
• Buy NVDA call spreads 2-4 months out around OpenAI event risk; structure for upside capture while limiting premium outlay in case the IPO becomes a short-term sell-the-news event.
• For patient capital, accumulate AVGO on pullbacks as the cleaner lagging beneficiary of diversification spend by model labs and hyperscalers, with a 6-18 month thesis and lower headline volatility than NVDA.